AI assistant
BiomX Inc. — Director's Dealing 2023
Dec 13, 2023
35099_dirs_2023-12-13_33917012-e7fe-4342-8ff9-b49bd653d137.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BiomX Inc. (PHGE)
CIK: 0001739174
Period of Report: 2023-12-11
Reporting Person: Oron Assaf (Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-11 | Common Stock Options - Right to Buy | $6.21 | D | 31500 | Disposed | 2030-03-25 | Common Stock (31500) | Direct |
| 2023-12-11 | Common Stock Options - Right to Buy | $0.2749 | A | 8290 | Acquired | 2030-03-25 | Common Stock (8290) | Direct |
| 2023-12-11 | Common Stock Options - Right to Buy | $7.02 | D | 33250 | Disposed | 2031-03-30 | Common Stock (33250) | Direct |
| 2023-12-11 | Common Stock Options - Right to Buy | $0.2749 | A | 8750 | Acquired | 2031-03-30 | Common Stock (8750) | Direct |
Footnotes
F1: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 31,500 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 8,290 shares, having an exercise price of $0.2749 per share.
F2: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
F3: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share.
F4: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.